(VIANEWS) – The NASDAQ ended the session with TherapeuticsMD (TXMD) jumping 14.66% to $4.85 on Tuesday while NASDAQ fell 0.59% to $10,983.78.
TherapeuticsMD’s last close was $4.23, 89.01% under its 52-week high of $38.50.
TherapeuticsMD, Inc. is a United States women’s health company. The company provides IMVEXXY, a treatment for moderate-to severe dyspareunia, and BIJUVA which is a bioidentical hormonal therapy combination of 17ss -estradiol, and progesterone to treat moderate-to–severe vasomotor conditions. TX-015HR is a transdermal progesterone cream. TX-016HR is an estradiol-progesterone cream. TX-018HR contains an estradiol-progesterone cream. TX-017HR and TX-018HR are potential transdermal patches. TX-019HR is an oral progesterone/estradiol formula. The company also produces and distributes generic and branded prescription prenatal vitamins, under the vitaTrue and vitaMedMD brands. It sells prescription drugs and prenatal vitamins to retail pharmacie distributors as well wholesale distributors. TherapeuticsMD, Inc., was established in Boca Raton, Florida in 2008.
Earnings per Share
TherapeuticsMD’s trailing 12 months profit per share is $-0.666
TherapeuticsMD’s value is way under its 50-day moving average of $7.15 and way below its 200-day moving average of $10.00.
The year-on-year revenue growth for quarterly declined 2.7%. We now have 86.42M in the 12 trailing months.
Annual Top and Bottom Value
TherapeuticsMD stock was valued at $4.85 as of 17:25 EST. This is way lower than its 52 week high of $38.50, and much higher than its 52-week low price of $1.99.
TherapeuticsMD’s sales growth is 8.6% for the current quarter and 3.6% for the next.
More news about TherapeuticsMD (TXMD).